Hospitalized patients
Acute Kidney Injury/Acute Kidney Disease (AKI/AKD) patients
Chronic kidney disease (CKD) patients
Pre-end stage renal disease (Pre-ESRD) outpatients
SMART on FHIR Integrated Care Platform: Engineered dynamic code refinements and logic optimizations to establish an interprofessional, intelligent care platform fully compliant with SMART on FHIR global interoperability standards. This architecture seamlessly integrates an automated AKI e-alert system, standardized inpatient-to-outpatient digital renal pathways, and an innovative outpatient pharmacy care model. By leveraging structured electronic health records, interactive BI dashboards, predictive AI models, and advanced CDS technologies, the platform delivers a standardized continuum of renal care from admission to outpatient follow-up, achieving early detection and systematic, proactive intervention.
This continuous algorithmic advancement and code optimization secured the prestigious 2026 "Taiwan 50 Excellent SMART App" Award (Clinical Decision Support Category) from the Ministry of Health and Welfare.
Pioneering Taiwan's first inpatient AKI alert system to redefine traditional kidney care.
First nationwide to baseline and compare local AKI seasonality trends against international data.
Established Taiwan’s first collaborative, two-stage clinical pharmacy care model within an interprofessional framework.
Built the sate-of-the-art outpatient kidney pharmacy platform, integrating interactive BI dashboards and predictive AI.
Deployed a globally unique AI predictive engine to forecast community-based AKI hospitalization risk indices.
Developed a patient-centric smart medication app, certified by an ROC Taiwan Patent and honored with the National Innovation Award.
Successfully system-wide scaling across 10 Chang Gung Memorial Hospital branches, ensuring health system-wide clinical consistency.
Honored with the prestigious "Taiwan 50 Excellent SMART App" Award (Clinical Decision Support Category) by the Ministry of Health and Welfare. This system (CA-AKI Hospitalization Risk Predictive and Decision Support System) successfully operationalizes the SMART on FHIR global interoperability framework, setting a national benchmark for standardized and intelligent healthcare architecture.
In KCGMH:
Generated 2,743 AKI alerts from February 11, 2020, to May 31, 2023, averaging a monthly incidence of 1.43 alerts per 100 patient visits at Kaohsiung Chang Gung Memorial Hospital.
Identified and flagged 2,666 high-risk AKI cases out of a total of 67,097 hospitalizations at Kaohsiung Chang Gung Memorial Hospital, ensuring early clinical detection.
Delivered 1,501 Pre-ESRD outpatient pharmaceutical care service visits between November 2021 and March 2023, seamlessly expanding renal tracking from wards to specialized clinics.
Cultivated a highly specialized clinical pharmacy workforce, with 26 clinical pharmacists successfully credentialed with dual-society certified renal care qualifications.
Conducted 54 multidisciplinary renal care training programs and developed 21 customized OSCE (Objective Structured Clinical Examination) modules to establish a standardized assessment framework.
Dose Optimization: Increased AKI medication adjustments by 1.8% and eGFR-guided renal dosing corrections by 4.7%.
Clinical Awareness Boost: Elevated AKI discharge diagnosis rates by 7.24%, sharpening physician alertness and reducing underreporting.
Dialysis Reduction: Prevented severe disease progression, reducing acute inpatient dialysis rates by 3.62%.
Medication Stewardship: Decreased nephrotoxic NSAIDs usage from 25.01% to 18.45%, outperforming the national benchmark.
Clinical Collaboration: Attained a benchmark physician acceptance rate of >60% for pharmacist-initiated recommendations.
Systemwide Scaling: Expanded the standardized system parallelly across 10 Chang Gung hospital branches since March 2022.
High-Performance Detection: Achieved 90.94% sensitivity, 100% specificity, and 99.65% accuracy for advanced AKI detection.
Environmental Resilience: Displayed stable seasonal trends throughout the March 2018 – May 2023 study period, while dynamically reflecting macro-level healthcare shocks such as the 2021 COVID-19 nationwide Level 3 alert
Physician Clinical Validation (n=81): Attained an 81.48% approval rating for the clinical usefulness of drug alerts, with 79.01% of physicians agreeing that the system directly improves AKI care.
Nursing Workflow Satisfaction (n=301): Achieved an 80% satisfaction rate for both information quality and rapid identification of patient care focus on the CDSS-AKI platform, with a 78% overall system satisfaction rate.
Patient-Reported Outcomes (n=49): Secured a >95% satisfaction rate among Pre-ESRD outpatients regarding disease self-management, pharmacist service attitude, and the quality of medication education.
2026 Journal Acceptance: Achieved official publication of the inpatient AKI e-alert system in the prestigious SCI journal (top 5%), Journal of Medical Systems (2026).
Published the world’s first AI predictive model for community-based AKI hospitalization risk in JMIR (2020)
Top Global Quality Award: Won the prestigious Best Quality Improvement Poster Award at the 33rd ISQua International Conference (2016).
Extensive Research Grants: Executed 9 major research projects (2016–2023), including 3 national grants (NSTC/NHRI) and 6 institutional grants.
Prolific Peer-Reviewed Publications: Authored >40 SCI journal articles (including AI medical informatics and clinical guidelines) and 29 conference papers (11 oral presentations, 18 posters) from 2016–2022
Global Knowledge Dissemination: Delivered 18 invited international and domestic presentations (2019–2023), scaling and promoting this benchmark care model to mainland China and 6 major medical institutions.
Policy Formulation Support: Leveraged domain expertise and clinical experience to support government planning, successfully facilitating pharmacist inclusion in the Pre-ESRD program with official National Health Insurance reimbursement since October 2021.
National Guideline Authorship: Contributed to the formulation and publication of 5 national kidney disease care guidelines and annual registries (2015–2022).
Top National Quality Awards: Clinched 3 Joint Commission Taiwan (JCT) National Healthcare Quality Awards (2020, 2021, 2023), a JCT Disease Care Quality Certification (2021), and 1 National Innovation Award.
2021 National Health Insurance Administration Disease Care Quality Certification - Kidney Disease Care Service
Intellectual Property & Patents: Secured 2 ROC Patents for the automated AKI e-alert architecture and the intelligent medication management app.
Academic & Leadership Impact: Won the Excellent Academic Spirit Award from the Taiwan Society of Health-System Pharmacists for 3 consecutive years; team experts have served as officers in the Taiwan Society of Nephrology since 2023 to shape nationwide AKI prevention policies.
